Lead Product(s) : BI 3720931
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : OXB
Deal Size : Inapplicable
Deal Type : Inapplicable
OXB’s Technology to Support Boehringer’s Gene Therapy for Cystic Fibrosis
Details : BI 3720931 is a first-in-class, inhaled lentiviral vector-based gene therapy designed to insert a functional copy of the CFTR gene in the DNA of airway epithelial cells for treating cystic fibrosis.
Product Name : BI 3720931
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 20, 2025
Lead Product(s) : BI 3720931
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : OXB
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BAY2599023
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Ultragenyx Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Bayer's Gene Therapy BAY 2599023 Showing Steady FVIII Activity, Safety in Trial
Details : Two of the six patients treated to date in this clinical study, both given the therapy at lowest dose, are still showing FVIII activity at more than one year post-treatment, its investigators report.
Product Name : DTX201
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 24, 2020
Lead Product(s) : BAY2599023
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Ultragenyx Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MB-207
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Mustang Bio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Mustang Bio Licenses LentiBOOST™ Technology from SIRION Biotech
Details : Mustang has acquired rights to SIRION’s LentiBOOST™ technology for the development of MB-207, Mustang’s lentiviral gene therapy for the treatment of patients with X-linked severe combined immunodeficiency.
Product Name : MB-207
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 10, 2020
Lead Product(s) : MB-207
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Mustang Bio
Deal Size : Undisclosed
Deal Type : Licensing Agreement